To further validate this finding, we performed H3K27ac ChIP-seq in control and HOXB13-KD LNCaP cells treated with either DMSO or CCS1477, a selective p300/CBP bromodomain inhibitor currently in clinical trials for advanced PCa and hematologic malignancies (16, 29). This evidence concerns the gene HOXB13 and hematologic disorder.